GoodRx Publishes Practical Guide to Retatrutide Availability, Dosage, and What Patients Should Know

GoodRx, the widely used prescription drug pricing and information platform, has published a detailed guide to retatrutide covering the drug's availability status, expected dosing from clinical trials, and practical considerations for patients. The guide addresses a growing need as public interest in retatrutide surges following the TRIUMPH-1 results while the drug remains unapproved anywhere in the world. ## What GoodRx's Guide Covers The GoodRx article provides an overview of retatrutide as an investigational triple-agonist drug targeting GLP-1, GIP, and glucagon receptors. It reviews the dosing regimens used in the TRIUMPH Phase 3 program — where participants received weekly subcutaneous injections at escalating doses — and notes that no approved dosage exists until Health Canada, the FDA, or other regulatory authorities grant marketing authorization. A central message of the guide is that retatrutide remains an investigational drug. Patients interested in the medication currently have limited pathways to access it: enrolment in an ongoing clinical trial, or — for patients with serious or life-threatening conditions — a physician-supervised special access request. The guide emphasizes that self-sourcing retatrutide from online vendors is unsafe and illegal. ## Dosing Background In the TRIUMPH-1 trial published in May 2026, participants received retatrutide at doses of up to 12 mg administered once weekly by subcutaneous injection. The dosing protocol began with a lower starting dose (2 mg) and escalated over several weeks to mitigate gastrointestinal side effects — a standard approach for incretin-based therapies. The trial achieved an average weight loss of up to 24.2% at 48 weeks at the highest dose. It is important to note that the final approved dosing schedule — should retatrutide receive marketing authorization — may differ from the clinical trial regimen. Dose optimization is a standard part of the regulatory review process. ## Availability and Regulatory Timeline Retatrutide has not received regulatory approval in any jurisdiction as of June 2026. Eli Lilly has stated that it plans to submit regulatory applications in the United States, Canada, the European Union, and other major markets in the second half of 2026. Based on standard FDA and Health Canada review timelines, a decision could come as early as 2027 assuming a complete submission package and no unexpected safety signals. In Canada, Health Canada's standard review takes approximately 300 to 400 calendar days for priority submissions. If Lilly submits with a priority filing, a decision could be expected in late 2027 or early 2028. However, these timelines are estimates and depend on the completeness of the application, the strength of the clinical data, and Health Canada's workload at the time of submission. ## Canadian Context For Canadians following retatrutide's development, the GoodRx guide highlights several important points: **Access pathways are limited.** Canadian patients who believe they may benefit from retatrutide before regulatory approval have two options: enrolling in a TRIUMPH clinical trial (several of which recruit at Canadian sites in Ontario, Quebec, British Columbia, and Alberta) or having their physician submit a request to Health Canada's Special Access Programme (SAP). The SAP allows patients with serious or life-threatening conditions to access investigational drugs on a case-by-case basis, but the process requires physician initiation and Health Canada approval. **No reimbursement clarity.** Even after Health Canada approval, retatrutide's public and private insurance coverage in Canada remains uncertain. Provinces negotiate drug prices with manufacturers through the pan-Canadian Pharmaceutical Alliance (pCPA) before listing on provincial formularies. Given the high efficacy and likely high cost of retatrutide, the pCPA process could extend the timeline between Health Canada approval and public coverage. **Cost considerations.** GoodRx's pricing context — noting that current FDA-approved GLP-1 medications carry list prices exceeding $1,000 per month in the United States — is relevant to the Canadian conversation. While Canadian drug prices are lower due to the Patented Medicine Prices Review Board (PMPRB), retatrutide is expected to be an expensive medication. Canadians without private insurance coverage for weight-loss medications may face significant out-of-pocket costs. **Online safety warnings.** The guide reinforces that any product currently marketed as "retatrutide" online is unregulated and potentially dangerous. Health Canada has issued similar warnings. Canadians should report any suspicious online retatrutide offerings to Health Canada's Health Product Complaint and Incident Reporting system. ## A Practical Resource for Patients GoodRx's guide fills an important gap in consumer-facing information about retatrutide. While much of the media coverage has focused on the TRIUMPH-1 clinical trial results and their implications for the obesity treatment landscape, practical questions from patients — How do I get it? How much will it cost? What dose would I take? — have received less attention. GoodRx's patient-oriented format addresses exactly these questions. The guide is particularly timely given the surge in online searches for retatrutide following the TRIUMPH-1 data release. Without authoritative, accessible information, patients may turn to unreliable sources, including online vendors selling counterfeit or contaminated product. Resources like the GoodRx guide help direct patients toward safe, evidence-based pathways. ## Sources - GoodRx: "Retatrutide for Weight Loss: Availability, Dosage, and More" (June 25, 2026) - Eli Lilly TRIUMPH-1 top-line results press release (May 2026) - Health Canada: Special Access Programme guidance - Patented Medicine Prices Review Board (PMPRB) pricing guidelines - pan-Canadian Pharmaceutical Alliance (pCPA) negotiation framework